Caribou Biosciences, Inc.
CRBU
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B celā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.46
Price-3.31%
-$0.05
1Y
Price
Market Cap
$144.804m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1019.4%
EBITDA Margin-1046.5%
Net Profit Margin-1128.7%
Free Cash Flow Margin-1019.4%
EBITDA Margin-1046.5%
Net Profit Margin-1128.7%
Free Cash Flow MarginRevenue
$11.203m
+0.4%
1y CAGR-19.6%
3y CAGR+22.5%
5y CAGREarnings
-$133.219m
+10.1%
1y CAGR-11.8%
3y CAGR-9.5%
5y CAGREPS
-$1.42
+10.7%
1y CAGR-1.8%
3y CAGR+2.7%
5y CAGRBook Value
$102.018m
$148.998m
Assets$46.980m
Liabilities$26.946m
DebtDebt to Assets
18.1%
-0.2x
Debt to EBITDAFree Cash Flow
-$101.640m
+9.5%
1y CAGR-2.0%
3y CAGR-3.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company